P-246: BMI variation in patients with Bardet Biedl and Alstrom syndrome treated with setmelanotide at pedro de Elizalde’s children hospital. Buenos Aires, Argentina
Hormone Research in Paediatrics · 04.11.2026 · 99 (Supplement_4)
DOI: 10.1159/hrp/adaag020.304 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hormone Research in Paediatrics, online erschienen am 04.11.2026. Verfasst von M V Britto und 6 weiteren Autor:innen.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction
Impaired ciliary signaling in the melanocortin-4 receptor (MC4R) pathway may contribute to obesity in patients with Bardet-Biedl syndrome (BBS) and Alström syndrome, rare genetic disorders associated with hyperphagia and early-onset severe obesity. Recently, an agonist of the Melanocortin 4 Receptor (MC4R), Setmelanotide, was approved for long-term weight control in syndromes affecting this pathway from 2 years old, revealing improvements in hunger and eating behavior, resulting in weight loss Objectives To describe BMI variation in patients with BBS and Alström syndrome treated with setmelanotide at the Nutrition Unit of Elizalde Children’s Hospital, Buenos Aires Methods Patients ≥2 years with a clinical diagnosis of BBS (Beales criteria) or Alström syndrome (Marshall criteria) and at least one related genetic variant were included. Five patients received 12 weeks of setmelanotide. In patients <12 years, the starting dose was 0.5 mg with titration up to 2.5 mg/day; in those ≥12 years, 1 mg up to 3 mg/day. Patients exhibiting favorable clinical outcomes and acceptable tolerability remained on treatment.
Results
Conclusions Bardet-Biedl (BBS) and Alström syndromes are characterized by hyperphagia, which frequently leads to the development of severe obesity. This study represents the first pivotal clinical trial in Argentina to evaluate a melanocortin-4 receptor (MC4R) agonist for these conditions. Given the low prevalence of these rare diseases, a non-traditional trial design was utilized. All participants demonstrated clinical tolerability, maintaining treatment beyond the 12-week mark. The most prevalent adverse events were cutaneous hyperpigmentation (100%) and injection-site erythema (20%). Significant BMI reduction was observed, supporting the clinical utility of setmelanotide in these populations
Zitieren
APA
Britto, M. V., Martin, E. A. S., Silberkasten, M., Andres, M. E., Franciulli, M., Serra, J., & Montaño, C. F. R. (2026). P-246: BMI variation in patients with Bardet Biedl and Alstrom syndrome treated with setmelanotide at pedro de Elizalde’s children hospital. Buenos Aires, Argentina. Hormone Research in Paediatrics, 99(Supplement_4). https://doi.org/10.1159/hrp/adaag020.304
Vancouver
Britto MV, Martin EAS, Silberkasten M, Andres ME, Franciulli M, Serra J, et al. P-246: BMI variation in patients with Bardet Biedl and Alstrom syndrome treated with setmelanotide at pedro de Elizalde’s children hospital. Buenos Aires, Argentina. Hormone Research in Paediatrics. 2026;99(Supplement_4). doi:10.1159/hrp/adaag020.304
BibTeX
@article{Britto2026,
author = {Britto, M V and Martin, E A San and Silberkasten, M and Andres, M E and Franciulli, M and Serra, J and Montaño, C F Rojas},
title = {P-246: BMI variation in patients with Bardet Biedl and Alstrom syndrome treated with setmelanotide at pedro de Elizalde’s children hospital. Buenos Aires, Argentina},
journal = {Hormone Research in Paediatrics},
year = {2026},
volume = {99},
number = {Supplement_4},
doi = {10.1159/hrp/adaag020.304}
}
EUVIMED